Carisbamate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Carisbamate
Accession Number
DB12338
Description

Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 215.63
Monoisotopic: 215.0349209
Chemical Formula
C9H10ClNO3
Synonyms
Not Available
External IDs
  • JNJ-10234094
  • RWJ-333369-000
  • YKP-509

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Carisbamate.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Carisbamate.
AclidiniumCarisbamate may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carisbamate.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Carisbamate.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Carisbamate.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Carisbamate.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Carisbamate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carisbamate.
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with Carisbamate.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

ATC Codes
N03AX19 — Carisbamate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Chlorobenzenes
Alternative Parents
Aryl chlorides / Carbamate esters / Secondary alcohols / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Alcohol / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Carbamic acid ester / Carbonyl group / Chlorobenzene / Hydrocarbon derivative / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
P7725I9V3Z
CAS number
194085-75-1
InChI Key
OLBWFRRUHYQABZ-MRVPVSSYSA-N
InChI
InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
IUPAC Name
(2S)-2-(2-chlorophenyl)-2-hydroxyethyl carbamate
SMILES
NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl

References

General References
Not Available
PubChem Compound
6918474
PubChem Substance
347828597
ChemSpider
5293671
ChEBI
135966
ChEMBL
CHEMBL2087003
ZINC
ZINC000030691363
Wikipedia
Carisbamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentComplex Partial Seizures / Epilepsies / Epilepsy, Complex Partial / Epilepsy, Localization Related1
3CompletedTreatmentEpilepsy, Complex Partial / Epilepsy, Partial, Motor / Epilepsy, Simple Partial / Focal Motor Epilepsy2
3TerminatedTreatmentEpilepsies / Seizures1
2CompletedTreatmentDiabetic Mononeuropathy / Diabetic Neuropathy, Painful / Diabetic Polyneuropathy / Neuralgia, Diabetic1
2CompletedTreatmentDiabetic Neuropathies1
2CompletedTreatmentEssential Tremor, Movement Disorders1
2CompletedTreatmentHerpes Zoster / Neuralgia / Postherpetic Neuralgia1
1Active Not RecruitingTreatmentHealthy Volunteers1
1RecruitingBasic ScienceLennox Gastaut Syndrome / Lennox-Gastaut Syndrome (LGS)2
1, 2Unknown StatusOtherAlcohol Abuse / Alcohol Dependence / Substance Abuse1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.15 mg/mLALOGPS
logP0.94ALOGPS
logP1.29ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)13.43ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity51.47 m3·mol-1ChemAxon
Polarizability20.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 16:00 / Updated on June 12, 2020 10:53